The same concerns arise in transgenic models of AD, where DHA decreases the amyloidgenic processing of amyloid precursor protein [64], leading to decreased production of plaque-forming amyloid-β both in vitro [65] and in vivo [66]. The gene discussed is APP; the disease is Alzheimer disease.